Ascentage Pharma Group International announce that its four abstracts selected for presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting are now available on ASCO's official website. These abstracts report on the Company's three lead drug candidates, including olverembatinib (HQP1351), the first and only China-approved third-generation BCR-ABL inhibitor; lisaftoclax (APG-2575), a BCL-2 selective inhibitor; and APG-2449, a FAK/ALK/ROS1 inhibitor. All lead drug candidates are being studied as they are investigational drugs and not approved in the US. Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting taking place during May 31, 2024 to June 4, 2024 (US local time). The ASCO Annual Meeting showcases the most cutting-edge research in clinical oncology and state-of-the-art
advanced cancer therapies and is the world's most influential and prominent scientific gathering of the clinical oncology community.